These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 4120362

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Decreased mortality of murine graft-versus-host disease by human chorionic gonadotropin.
    Slater LM, Bostick W, Fletcher L.
    Transplantation; 1977 Jan; 23(1):103-4. PubMed ID: 13524
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B, Uharek L, Gaska T, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993 Jan; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [Abstract] [Full Text] [Related]

  • 28. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S, Yacovlev E, Gelfand Y, Shabat Y, Slavin S.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [Abstract] [Full Text] [Related]

  • 29. Use of soluble histocompatibility antigen(s) in the control of transplantation reactions: possible dissociation of the roles of H-2 and non-H-2 antigens in the prevention of mortality induced by graft-versus-host reaction.
    Halle-Pannenko O, Abuaf N, Mathé G.
    Transplant Proc; 1976 Jun; 8(2):161-72. PubMed ID: 7038
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Jun; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E, Weiss L, Kasir J, Zeira M, Slavin S, Shapira MY.
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Suppression of graft versus host reactivity by a single host-specific blood transfusion to prospective donors of hemopoietic cells.
    Knulst AC, Bril-Bazuin C, Ruizeveld de Winter JA, Benner R.
    Transplant Proc; 1990 Aug; 22(4):1975-6. PubMed ID: 2389502
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.